Jolanta Citko

Olsztyn, WN 10561, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens.

Journal: Viruses

Published: February 03, 2023

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.

Journal: World journal of gastroenterology

Published: August 26, 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study.

Journal: Journal of clinical medicine

Published: July 23, 2022

HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.

HCV Genotype Has No Influence on the Incidence of Diabetes-EpiTer Multicentre Study.

Journal: Journal of clinical medicine

Published: December 09, 2021

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection.

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection.

Journal: Journal of clinical medicine

Published: November 28, 2021

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics.

Journal: Journal of clinical medicine

Published: June 13, 2021

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.

Journal: World journal of gastroenterology

Published: January 26, 2021

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.

Journal: Annals of gastroenterology

Published: September 13, 2020

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?

Journal: Journal of gastroenterology and hepatology

Published: September 10, 2020

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Real-world effectiveness and safety of direct-acting antivirals in patients with cirrhosis and history of hepatic decompensation: Epi-Ter2 Study.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: August 30, 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA.

Journal: Expert review of anti-infective therapy

Published: June 16, 2020

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

Journal: Polish archives of internal medicine

Published: February 08, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026